You are here

  • Home
  • Archive
  • Volume 82, Issue 2
  • Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al
Free
  1. Adrian Ciurea1,
  2. Axel Finckh2
  1. 1 Rheumatology, University Hospital Zurich, Zurich, Switzerland
  2. 2 Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland
  1. Correspondence to Professor Adrian Ciurea, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; adrian.ciurea{at}usz.ch

http://dx.doi.org/10.1136/annrheumdis-2020-219420

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We would like to thank Ruyssen-Witrand et al for their interest in our study1 and their data from French patients with rheumatoid arthritis collected during the first wave of the COVID-19 pandemic through an online survey.2 Despite the fact that up to 70% of medical consultations could not be performed as planned due to confinement, adherence to immunosuppressive medication was very high (>80%), confirming our findings in Switzerland. This is all the more remarkable, as confinement measures were more stringent in France than in Switzerland. The rapid switch from physical visits to remote ways of patient–physician interaction, as also documented in their analysis, most probably led to these encouraging results.

    Ethics statements

    Patient consent for publication

    References

    1. ↵
      2. Ciurea A ,
      3. Papagiannoulis E ,
      4. Bürki K , et al
      . Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss clinical quality management cohort. Ann Rheum Dis 2021;80:238–41.doi:10.1136/annrheumdis-2020-218705 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32963052
      OpenUrlAbstract/FREE Full Text
    2. ↵
      2. Ruyssen-Witrand A ,
      3. Soubrier M ,
      4. Basch A , et al
      . Correspondence on “Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort”. Ann Rheum Dis 2023;82:e32.doi:10.1136/annrheumdis-2020-219409

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors AC and AF wrote the manuscript and approved the final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests AC reports personal fees from AbbVie, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer, outside the submitted work.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles